Last reviewed · How we verify

Stimulant Therapy

Otsuka Pharmaceutical Development & Commercialization, Inc. · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Stimulant Therapy is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc.. It is currently FDA-approved.

Stimulant therapy is used to treat conditions such as Attention Deficit Disorder With Hyperactivity and Prescription Drug Abuse, as well as Frontotemporal Lobar Degeneration. The exact mechanism of stimulant therapy is related to gene therapy, specifically targeting genes involved in the treatment.

At a glance

Generic nameStimulant Therapy
SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Stimulant Therapy

What is Stimulant Therapy?

Stimulant Therapy is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc..

Who makes Stimulant Therapy?

Stimulant Therapy is developed and marketed by Otsuka Pharmaceutical Development & Commercialization, Inc. (see full Otsuka Pharmaceutical Development & Commercialization, Inc. pipeline at /company/otsuka-pharmaceutical-development-commercialization-inc).

What development phase is Stimulant Therapy in?

Stimulant Therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing